| 中文名称 | 红陪酚 |
| 英文名称 | PURPUROGALLIN |
| CAS号 | 569-77-7 |
| 分子式 | C11H8O5 |
| 分子量 | 220.18 |
| EINECS号 | 209-324-9 |
| 熔点 | 275 °C (dec.)(lit.) |
| 沸点 | 321.11°C (rough estimate) |
| 密度 | 1.3824 (rough estimate) |
| 折射率 | 1.5140 (estimate) |
| LogP | 2.050 (est) |
| 溶解度 | 可溶于DMSO(少许)、甲醇(少许) |
| 形态 | 固体 |
| 酸度系数(pKa) | 6.75±0.20(Predicted) |
| 颜色 | 深棕色低熔点 |
| 默克索引编号 | 7946 |
| 稳定性 | 空气敏感 |
| 危险品标志 | Xi |
| 危险类别码 | 36/37/38 |
| 安全说明 | 26-36 |
| WGK Germany | 3 |
| RTECS号 | DE8380000 |
IC50: 0.2 µM (xanthine oxidase)
Purpurogallin (50 or 100 µM; 7 or 25 hours; BV2 murine microglial cells) treatment attenuates the production of pro-inflammatory cytokines, including interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) by suppressing their mRNA and protein expression in LPS-stimulated BV2 microglial cells.
Purpurogallin (100 µM; 75-120 minutes; BV2 murine microglial cells) exhibits anti-inflammatory properties by suppressing the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase signaling pathways in LPS-stimulated BV2 microglial cells.
RT-PCR
| Cell Line: | BV2 murine microglial cells |
| Concentration: | 50 or 100 µM |
| Incubation Time: | 7 or 25 hours |
| Result: | Attenuated the production of pro-inflammatory cytokines, including interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) by suppressing their mRNA and protein expression. |
Western Blot Analysis
| Cell Line: | BV2 murine microglial cells |
| Concentration: | 100 µM |
| Incubation Time: | 75 minutes, 90 minutes, 120 minutes |
| Result: | Suppressed the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase signaling pathways. |
Purpurogallin (100-400 μg/kg; intraperitoneal injection; for 48 or 72 hours; male Sprague-Dawley rats) exerts its neuroinflammation effect through the dual effect of inhibiting IL-6 and TNF-α mRNA expression and reducing HMGB1 protein and mRNA expression.
| Animal Model: | Fifty-four male Sprague-Dawley rats (250-350 g) with subarachnoid hemorrhage (SAH) |
| Dosage: | 100 μg/kg, 200 μg/kg, 400 μg/kg |
| Administration: | Intraperitoneal injection; for 48 or 72 hours |
| Result: | Dose-dependently reduced HMGB1 protein expression. High dose reduced TNF-α and HMGB1 mRNA levels. |